Ligustrazine was shown to improve dyslipidemia by downregulation of the progestin and adipoQ receptor 3 (PAQR3) and inhibition of the SCAP/SREBP1c pathway in ApoE−/− mice fed with a high fat diet [89,90]. This evidence concerns the gene SREBF1 and metabolic syndrome.